ANNX VS IMRA Stock Comparison

Performance

ANNX
10/100

ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

IMRA
100/100

IMRA returned 346.61% in the last 12 months. Based on the other stocks in it's sector with an average return of -24.53%, it's performance is above average giving it a grade of 100 of 100.

Sentiment

ANNX
72/100

ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.

IMRA
10/100

IMRA does not have any recent conclusive social sentiment.

Technicals

ANNX
64/100

ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

IMRA
89/100

IMRA receieves a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

ANNX
10/100

ANNX has missed earnings 7 times in the last 20 quarters.

IMRA
64/100

IMRA has missed earnings 2 times in the last 20 quarters.

Profit

ANNX
10/100

Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.

IMRA
10/100

Out of the last 9 quarters, IMRA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ANNX
49/100

ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

IMRA
65/100

IMRA has had a higher than average amount of volatility over the last 12 months giving it a grade of 65 of 100.

Forecast

ANNX

"Forecast" not found for ANNX

IMRA
10/100

IMRA has no analyst ratings.

Dividend

ANNX

"Dividend" not found for ANNX

IMRA
10/100

IMRA has not paid a dividend in the last 5 years.

All score calculations are broken down here to help you make more informed investing decisions

Annexon, Inc. Common Stock Summary

Nasdaq / ANNX

Healthcare

Biotechnology

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

IMARA Inc. Common Stock Summary

Nasdaq / IMRA

Healthcare

Biotechnology

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Power up your portfolio